Latest Hodgkin's lymphoma Stories
Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too Raleigh, North
DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/7dhkqb/investigation) has announced the addition of the "Investigation
Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. Raleigh, NC
A new study indicates that an investigational drug for relapsed Non-Hodgkin’s Lymphoma called pixantrone (Pixuvri) is safer for the heart than the current front-line treatment. Raleigh,
Scientists say patients with certain forms of aggressive Non-Hodgkin’s Lymphoma are more likely to survive if they respond well to their first treatment. Raleigh,
NIH researchers say risks from occupational exposures such as PCBs cannot be ruled out. Raleigh, NC (PRWEB) March 15, 2014 Researchers with the National
Researchers say a combination of bendamustine and rituximab may be just as effective and less toxic than standard chemotherapy for indolent lymphomas. Raleigh,
Targeted drug aims to address high recurrence and lower survival in people with B-cell cancers. Raleigh, NC (PRWEB) March 10, 2014 The Non-Hodgkin’s
WASHINGTON, March 10, 2014 /PRNewswire-USNewswire/ -- A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment
Two new studies in major medical journals may help doctors understand how Non-Hodgkin’s Lymphoma starts, and predict treatment outcomes. Raleigh, NC (PRWEB)
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.